Form 4: Amneal Pharmaceuticals Executive Vice President Tasos Konidaris Reports Stock Transactions
SEC Form 4 Filing
Executive Vice President and CFO of Amneal Pharmaceuticals, Tasos Konidaris, reports acquisition and disposal of Class A Common Stock and Restricted Stock Units.
Summary
- Tasos Konidaris, Executive Vice President & CFO of Amneal Pharmaceuticals, reported transactions involving Class A Common Stock and Restricted Stock Units.
- On March 3, 2025, Konidaris acquired shares through the vesting of restricted stock units and performance-based restricted stock units.
- Simultaneously, shares were disposed of to cover tax withholding obligations related to the vesting of these units.
- Additional shares were acquired on March 4, 2025, through the vesting of restricted stock units, with a corresponding disposal for tax obligations.
- The reported transactions altered Konidaris's direct ownership of Amneal Pharmaceuticals Class A Common Stock and derivative securities.
Sentiment
Score: 6
Explanation: The document reflects routine executive stock transactions related to compensation. It doesn't contain overtly positive or negative information, hence a neutral sentiment score.
Positives
- The vesting of restricted stock units and performance-based restricted stock units indicates that the company is meeting certain performance thresholds.
- The executive's continued holding of a significant number of shares demonstrates confidence in the company's future.
Negatives
- The disposal of shares to cover tax obligations, while standard, reduces the overall holdings of the executive.
Risks
- Fluctuations in the stock price could impact the value of the executive's holdings.
- Future vesting of restricted stock units is contingent upon continued employment and potentially performance metrics.
Future Outlook
The document details future vesting schedules for restricted stock units and performance-based restricted stock units, indicating potential future stock issuances.
Industry Context
Executive stock transactions are a common occurrence in publicly traded companies and are closely monitored by investors for insights into management's confidence in the company's prospects.
Comparison to Industry Standards
- Executive compensation packages often include restricted stock units and performance-based restricted stock units to align management's interests with those of shareholders.
- The vesting schedules and performance metrics associated with these units are typically benchmarked against industry peers to ensure competitiveness and effectiveness.
- Companies like Teva Pharmaceuticals, Mylan (now Viatris), and Sun Pharmaceutical Industries also utilize similar equity-based compensation strategies for their executives.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in the number of outstanding shares.
- Employees may be affected by the vesting of restricted stock units, which can serve as an incentive.
Key Dates
| Date | Description |
|---|---|
| 03/03/2022 | Reporting person was granted performance-based restricted stock units, scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. |
| 03/03/2022 | The reporting person was granted 181,159 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. |
| 03/03/2023 | The reporting person was granted 229,358 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. |
| 03/03/2025 | Date of multiple transactions involving Class A Common Stock and Restricted Stock Units. |
| 03/04/2024 | The Reporting Person was granted 175,926 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. |
| 03/04/2025 | Date of additional transactions involving Class A Common Stock and Restricted Stock Units. |
| 03/05/2025 | Date of signature for the report. |
| 03/03/2026 | The restricted stock units vest in four equal annual installments beginning on March 3, 2026. |
| 02/28/2028 | Any earned performance-based restricted stock units vest in full on February 28, 2028, the last day of the performance period. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.